- Home
- EAT vs LEGN Comparison
EAT vs LEGN Comparison
Compare EAT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EAT | LEGN |
|---|---|---|
| Founded | 1975 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EAT | LEGN |
|---|---|---|
| Price | $149.87 | $22.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 13 |
| Target Price | ★ $165.00 | $69.58 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 01-28-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.76 | N/A |
| EPS | ★ 9.64 | N/A |
| Revenue | ★ $5,594,400,000.00 | $909,045,000.00 |
| Revenue This Year | $7.93 | $68.52 |
| Revenue Next Year | $5.27 | $48.63 |
| P/E Ratio | $15.51 | ★ N/A |
| Revenue Growth | 23.18 | ★ 74.75 |
| 52 Week Low | $100.30 | $21.19 |
| 52 Week High | $192.22 | $45.30 |
Technical Indicators
Market Signals| Indicator | EAT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.58 | 33.52 |
| Support Level | $144.52 | $21.19 |
| Resistance Level | $154.83 | $23.24 |
| Average True Range (ATR) | 5.77 | 1.04 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 75.46 | 21.26 |
Price Performance
Historical ComparisonAbout EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.